Bain Capital Life Sciences
Boston, Massachusetts, United StatesFounded 2016
Bain Capital Life Sciences (BCLS) is a life sciences-focused investment firm founded in 2016 as part of Bain Capital. It invests in biopharmaceutical, medical device, diagnostic, and life science tool companies across the globe, targeting companies that drive medical innovation to improve the lives of patients with unmet medical needs.
47% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deals in the last 12 months vs 6 prior). Average disclosed round size is $192.1M (across 53 rounds with reported amounts).
Portfolio
55
Fund Size
$3B
Top Stage
Series B
Last 12 Mo
2
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
55 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Merida Biosciences | Series A | $121M | Aug 2026 |
| KKailera | Series B | $600M | Oct 2025 |
| AAbcuro, Inc. | Series C | $200M | Feb 2025 |
 Timberlyne Therapeutics | Series A | $180M | Jan 2025 |
 Apreo Health | Series B | $130M | Jan 2025 |
| AApreo | Unknown | $130M | Jan 2025 |
 Kailera Therapeutics | Series A | $400M | Oct 2024 |
 Cardurion Pharmaceuticals | Series B | $260M | Jul 2024 |
 Cerevasc | Series B | $70M | May 2024 |
 Cidara Therapeutics | Unknown | $240M | Apr 2024 |
| AAiolos Bio | Series A | $245M | Oct 2023 |
| AAdaRx Pharmaceuticals | Series C | $200M | Aug 2023 |
| KKyverna Therapeutics | Series B | $60M | Aug 2023 |
 Heartflow | Series F | $215M | Apr 2023 |
| AAdarx | Series C | $46M | Jan 2023 |
 Jnana Therapeutics | Series C | $107M | Nov 2022 |
 Emalex Biosciences | Series D | $250M | Nov 2022 |
| EEmalex | Series D | $250M | Nov 2022 |
 Rivus Pharmaceuticals | Series B | $132M | Sep 2022 |
| JJenaValve Technology | Series C | $100M | Aug 2022 |
 Nimbus | Unknown | $125M | Jan 2022 |
 JenaValve | Series C | $100M | Jan 2022 |
| RRivus Pharma | Series B | $132M | Jan 2022 |
 Freenome | Series D | $300M | Dec 2021 |
 ViaCyte | Unknown | $45M | Jun 2021 |
Page 1 of 3
Top Co-Investors
RA Capital Management18 shared
Redmile Group11 shared
Cormorant Asset Management10 shared
Omega Funds7 shared
Atlas Venture7 shared
Foresite Capital7 shared
Perceptive Advisors6 shared
Rock Springs Capital6 shared
HBM Healthcare Investments6 shared
Frazier Healthcare Partners6 shared
The Invus Group, LLC6 shared
OrbiMed6 shared
T. Rowe Price5 shared
Longitude Capital5 shared
Viking Global Investors5 shared
Wellington Management5 shared
Third Rock Ventures5 shared
Vivo Capital5 shared
Catalio Capital Management4 shared
Last updated: 7 September 2026